Review of the safety and efficacy of ustekinumab - Wikidata - awgldk - TriplyDB

Review of the safety and efficacy of ustekinumab

Review of the safety and efficacy of ustekinumab

http://www.wikidata.org/entity/Q34625984

about

Ustekinumab for the treatment of Crohn's disease: can it find its niche?Ustekinumab in Crohn's disease: evidence to date and place in therapy Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.Management of cutaneous disorders related to inflammatory bowel disease.Late reaction to ustekinumab infusion.Immunoregulatory function of PIR-A/B+ DCs in the inflammatory responses of dextran sodium sulfate-induced colitis.

P2860

Q26771890-D01D6B45-85DD-4FA5-8209-143EF462416F Q28073787-D46A5D30-3094-43C3-987D-C9D62614C9E3 Q30620977-3EA319E4-ABFE-40F9-8647-BD8AAB2EC4D5 Q36158922-45D9BDD3-2383-4C21-B643-8356DDEF1F7F Q36249305-CF8884F3-597E-47BE-8F45-3C2EF433D0DE Q38632657-75E67815-9C17-4E63-9374-C1EEFA8D9613 Q38798137-E4011441-2559-4FB8-9EA9-0CD51BA0D5E6 Q39164487-3221373A-5A39-48E1-AC0B-F996EFBD28D0 Q42406766-FE11155A-CC20-45A4-A0E4-412769101B78 Q42879699-BB336AAA-F08E-4B1D-BB71-3EAD7CB89554 Q44126280-C548089F-AA16-40A6-87F1-01C78B778595

P2860

Review of the safety and efficacy of ustekinumab

http://www.wikidata.org/entity/Q34625984

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Review of the safety and efficacy of ustekinumab

@ast

Review of the safety and efficacy of ustekinumab

@en

Review of the safety and efficacy of ustekinumab

@nl

type

label

Review of the safety and efficacy of ustekinumab

@ast

Review of the safety and efficacy of ustekinumab

@en

Review of the safety and efficacy of ustekinumab

@nl

prefLabel

Review of the safety and efficacy of ustekinumab

@ast

Review of the safety and efficacy of ustekinumab

@en

Review of the safety and efficacy of ustekinumab

@nl

P1433

Q34625984-9C95E489-9BD7-4D0F-A669-49DDC8602A02

P1476

Q34625984-EE3E7665-7D1D-4959-8DF2-72EC6C10A4EE

P2093

Q34625984-0950DB84-66C2-4300-970F-CC9D521C35AF

Q34625984-2DEFDD04-7D3E-475D-9DED-5F79CD8D7FBB

Q34625984-A08851A4-362A-453E-9001-A82833E210CA

P2860

Q34625984-1754E0F3-2F09-4C86-8DFD-0402DA4B6D93

Q34625984-266412C9-1796-4A4E-964C-96F032650B9A

Q34625984-2875C4EC-07C3-48EF-990D-DD784563AB83

Q34625984-35AAB2F6-9E70-4510-B2DA-8B413D9F77D2

Q34625984-3C9B7B9B-B6E6-49EA-ACA5-4EACFCDBC17E

Q34625984-4299EC95-C348-4F4D-982A-AA8F591333F1

Q34625984-491B7E57-E8F2-4C1B-9F9B-24590FF17B5E

Q34625984-5495F056-3454-4E85-B656-A8ABDD377418

Q34625984-5FFDFD46-9E1B-4774-9E9A-2C19C6887670

Q34625984-6491B366-6A79-4041-BBE2-4BDF0EDE30E1

P304

Q34625984-366E29D1-E5E1-4436-836E-FB9E653BAD86

P31

Q34625984-8AA23902-503F-47CD-874D-03277B4B5407

Q34625984-cc7d191f-190e-4a86-b377-9bea47546d33

P356

Q34625984-C39BDAC1-8EAD-441F-8791-1A6907B7A1D8

P433

Q34625984-79C9EC20-3621-4428-8202-162D33E099E2

P478

Q34625984-A989C178-7D1F-41BA-B4B2-8A5EC5BB513F

P577

Q34625984-F460AC8E-876A-4B4E-911E-30C7B3E304D2

P698

Q34625984-43254449-8A77-4A85-ACA3-19B6C1BF01DE

P932

Q34625984-E9CDB9B0-C97A-48E5-A1D4-320843D8A061

P356

1756283X10374216

P1433

Therapeutic Advances in Gastroenterology

P1476

Review of the safety and efficacy of ustekinumab

@en

P2093

Ellen J Scherl

http://www.w3.org/2001/XMLSchema#string

Ryan U Warren

http://www.w3.org/2001/XMLSchema#string

Sheila Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Certolizumab pegol for the treatment of Crohn's disease

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

Anti-interleukin-12 antibody for active Crohn's disease

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

P304

321-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X10374216

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21180612

http://www.w3.org/2001/XMLSchema#string

P932

3002587

http://www.w3.org/2001/XMLSchema#string